Table 3.
Summary of base-case cost-effectiveness results
| Effectiveness components | SAP with automated insulin suspension arm | CSII-alone arm | Difference |
|---|---|---|---|
| Cohort at increased risk for hypoglycemia | |||
| Total costs, SEK (EUR) | 2,671,858 (279,969) | 2,409,462 (252,473) | 262,396 (27,495) |
| Direct costs, SEK (EUR) | 865,183 (90,657) | 491,287 (51,479) | 373,896 (39,178) |
| Treatment | 659,570 (69,112) | 141,864 (14,865) | 517,706 (54,247) |
| Management | 19,125 (2004) | 18,969 (1988) | 156 (16) |
| Cardiovascular disease | 37,066 (3884) | 36,360 (3810) | 706 (74) |
| Renal complications | 92,031 (9643) | 89,539 (9382) | 2492 (261) |
| Ulcer/amputation/neuropathy | 50,803 (5323) | 50,224 (5263) | 579 (61) |
| Ophthalmic complications | 6588 (690) | 6532 (684) | 56 (6) |
| Quality-adjusted life expectancy (QALY) | 13.110 | 11.233 | 1.877 |
| ICER, SEK (EUR) per QALY gained | 139,795 (14,648) | ||
| Cohort with uncontrolled HbA1c at baseline | |||
| Total costs, SEK (EUR) | 1,925,040 (201,713) | 1,656,141 (173,537) | 268,899 (28,176) |
| Direct costs, SEK (EUR) | 742,442 (77,796) | 391,958 (41,071) | 350,484 (36,725) |
| Treatment | 467,551 (48,992) | 99,090 (10,383) | 368,461 (38,609) |
| Management | 13,438 (1399) | 13,133 (1376) | 305 (32) |
| Cardiovascular disease | 72,406 (7587) | 72,508 (7598) | −102 (−11) |
| Renal complications | 137,527 (14,410) | 153,457 (16,080) | −15,930 (−1,669) |
| Ulcer/amputation/neuropathy | 34,722 (3638) | 37,238 (3911) | −2516 (−264) |
| Ophthalmic complications | 5149 (539) | 5190 (544) | −41 (4) |
| Quality-adjusted life expectancy, QALYs | 9.224 | 8.157 | 1.067 |
| ICER, SEK (EUR) per QALY gained | 251,896 (26,395) | ||
Costs are presented in SEK with the equivalent value in euros (EUR) given in parenthesis. The exchange rate for the conversion from SEK to EUR was 1 SEK 1 = 0.10478 EUR (date 1 August 2017)
ICER Incremental cost-effectiveness ratio, QALY quality-adjusted life year